Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.
Domain
bluejaytx.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$182.0M
Founded
2018
No technologies detected yet for this company.
Frequently Asked Questions
What technologies does Bluejay Therapeutics use?+
We have not yet detected technologies for Bluejay Therapeutics.
What industry is Bluejay Therapeutics in?+
Bluejay Therapeutics operates in the Biotechnology industry.
Where is Bluejay Therapeutics based?+
Bluejay Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026